Galcanezumab for the prevention of migraine.

Document Type

Article

Abstract

Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.

Medical Subject Headings

Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcitonin Gene-Related Peptide; Humans; Migraine Disorders

Publication Date

3-1-2021

Publication Title

Pain Manag

ISSN

1758-1877

Volume

11

Issue

2

First Page

101

Last Page

112

PubMed ID

33291980

Digital Object Identifier (DOI)

10.2217/pmt-2020-0030

This document is currently not available here.

Share

COinS